Houston, United States
Research view
Lung cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- EGFR 301
- PD-L1 162
- PD-1 157
- KRAS 98
- ALK 72
- TP53 10
- HER2 63
- MET 43
- PI3K 1
- STAT3 0
- AKT 2
- ROS1 27
- mTOR 0
- VEGF 23
- BRAF 9
- RET 9
- NRF2 1
- MAPK 1
- ERK 0
- STING 0
- STK11 7
- YAP 1
- DLL3 27
- CTLA-4 15
- RAS 15
- CTNNB1 0
- TROP2 13
- JAK 1
- HIF-1 1
- AMPK 0
- PARP 2
- KEAP1 5
- JNK 0
- MYC 1
- B7-H3 14
- GPX4 0
- HER3 11
- PTEN 4
- MEK 1
- TIGIT 6
- FGFR 3
- IL-6 1
- PPAR 0
- EZH2 2
- HDAC 0
- PRMT5 7
- FAK 0
- COX-2 0
- HMGB1 0
- NTRK 5
- AXL 3
- BCL-2 0
- CDK4/6 4
- CXCR4 1
- CD47 1
- METTL3 0
- NLRP3 0
- SHP2 0
- HSP90 0
- MDM2 1
EU-13 is a filter, not a ranking: it only narrows the list.
New York, United States
Shanghai, China
Boston, United States
Jinan, China
Shanghai, China
Beijing, China
Boston, United States
Guangzhou, China
Hangzhou, China
Rochester, United States
Guangzhou, China
Stanford, United States
Villejuif, France
Seoul, South Korea
New York, United States
Tampa, United States
Boston, United States
Toronto, Canada
Harbin, China
Zhengzhou, China
Chengdu, China
Tokyo, Japan
San Diego, United States
24 of 62+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
PF-07284892 in Participants With Advanced Solid Tumors
“The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue”Registry text, quoted unchanged. Source
Terminated
“Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions”Registry text, quoted unchanged. Source
Terminated
“Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source
Suspended
“Sponsor decision”Registry text, quoted unchanged. Source
Terminated
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
“Business reasons”Registry text, quoted unchanged. Source
Terminated
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
“Adjustment of the applicant's research and development strategy”Registry text, quoted unchanged. Source
Terminated
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
“Not related to safety concerns or lack of efficacy”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 145
- Organoids 47
- Mendelian Randomization Analysis 66
- CRISPR-Cas Systems 43
- Gene Expression Profiling 314
- Sequence Analysis, RNA 43
- Whole Genome Sequencing 13
- Exome Sequencing 18
- Proteomics 133
- Metabolomics 67
- Mass Spectrometry 25
- Flow Cytometry 73
- Immunohistochemistry 191
- Liquid Biopsy 76
- Circulating Tumor DNA 83
- Xenograft Model Antitumor Assays 616
- Positron-Emission Tomography 70
- Magnetic Resonance Imaging 115
- Machine Learning 290
- Deep Learning 210
- Cohort Studies 289
- Genome-Wide Association Study 75
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.